Efficacy of alendronate in the treatment of the SAPHO syndrome

Journal of Clinical Rheumatology

Volumn 14, Issue 3, 2008, Pages 183-184

  Fioravanti, Antonella ^a   Cantarini, Luca ^a   Burroni, Luca ^a   Mazzei, Maria Antonietta ^a   Volterrani, Luca ^a   Galeazzi, Mauro ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; C REACTIVE PROTEIN; HYDROXYPROLINE; MEDRONATE TECHNETIUM TC 99M; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE EROSION; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE SWELLING; CASE REPORT; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CLAVICLE; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT SOLE; HAND PALM; HEAT SENSATION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYDROXYPROLINE URINE LEVEL; HYPEROSTOSIS; ILIAC BONE; LOW BACK PAIN; LYMPHOCYTIC INFILTRATION; MALAISE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOMYELITIS; OSTEOSCLEROSIS; PAIN; PAPULAR RASH; PELVIS RADIOGRAPHY; PERIOSTEUM; PRESSURE SENSATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; PUSTULOSIS; REMISSION; RIGIDITY; SACROILIAC JOINT; SAPHO SYNDROME; SKIN BIOPSY; SWELLING; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ACQUIRED HYPEROSTOSIS SYNDROME; ADULT; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS;

EID: 48249098312     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318177a64f     Document Type: Article

References (10)

1. Cotten A, Flipo RM, Mentre A, et al. SAPHO syndrome. Radiographics. 1995;15:1147-1154.
2. Kopterides P, Pizakis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum. 2004;50:2970-2973.
3. Solau-Gervais E, Soubrier M, Gerot I, et al. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology. 2006;45:339-342.
4. Rothschild B, Schils J, Lavelle H. Potential therapeutic approach to SAPHO. Semin Arthritis Rheum. 2000;29:332-334.
5. Anderson R. Effective treatment with interferon α in chronic recurrent multifocal osteomyelitis. J Interferon Cytokine Res. 1995;15: 837-838.
6. Gallagher KT, Roberts RL, MacFarlane JA, et al. Treatment of chronic recurrent multifocal osteomyelitis with interferon gamma. J Pediatr. 1997;131:470-472.
7. Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin InvestigDrugs. 2006;15:1229-1233.
8. Pennanen N, Lapinjoki S, Urtti A, et al. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNF-α secretion from RAW 264 cells. in vitro Pharm Res. 1995;12:916-922.
9. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int. 1986;36:227-233.
10. Coukell AJ, Markham A. Pamidronate: a review of its use in the management of osteolytic bone metastases, tumor induced hypercalcemia and Paget's disease of bone. Drugs Aging. 1998;12:149 - 168.